ArticleEmerging infectious diseases2026
Dengue Incidence, Seroprevalence, and Expansion Factors from Active Surveillance, Brazil, 2016-2021.
Article in Emerging infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dengue is hyperendemic in Brazil and is underestimated by passive surveillance. To better understand dengue incidence, we conducted epidemiologic analyses among participants, 2-59 years of age, from the placebo arm of a phase 3 dengue vaccine trial. During 2016-2021, a total of 5,947 participants contributed to 22,028 person-years of follow-up. We identified and virologically confirmed dengue (VCD), Zika, and chikungunya infections. We observed VCD and chikungunya incidence heterogeneity by age, geographic location, and study year. Children 2-6 years of age experienced the highest VCD (2.33/100 person-years) and chikungunya (1.02/100 person-years) incidence. VCD peaked in 2019 (n = 148) whereas chikungunya peaked in 2017 (n = 51). VCD incidence rates from active surveillance were generally higher than those reported to the national passive surveillance system; expansion factor range was <1-9.5 by municipality. Active surveillance is critical to better understand and characterize dengue epidemiology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.